Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces Enterprise 3D Modeling Deal With AI Revenue Driving Growth (click to learn more)
Biosenta's Tri-Filler(TM) Nanoparticles Achieve 100% Killing of Pathogens (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Ensysce Biosciences Inc
ENSC
Alternate Symbol(s):
ENSCW
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
NDAQ:ENSC - Post by User
Ensysce Biosciences Inc
<< Previous
Bullboard Posts
Next >>
(0)
•••
PressRelease
X
Post by
PressRelease
on May 12, 2023 4:40pm
67 Views
Post# 35446291
New Press Release - Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
New Press Release - Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc.(NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public...
read article.
<< Previous
Bullboard Posts
Next >>
Redefining the future of regenerative medicine
A Canadian mineral company at the crossroads of electrification and defense
Almonty Industries – NASDAQ listing, Pentagon, world-class mine, critical raw materials: ride the perfect wave
New Analyst Report Lifts Almonty Target Price to CDN$5.50
This junior hydrogen stock is the epitome of undervalued
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Graphite Creek Project Approved for FAST-41 Federal Permitting Dashboard
Mullen Group acquires company expected to generate annualized revenues of $300 million
Despite turbulent markets this logistics company continues to grow
Merger Announced to Create a Leading Yukon Copper-Gold Exploration and Development Company
Graphite One and Lucid Enter into Second Non-Binding Supply Agreement